Why Amylyx is pulling ALS drug Relyvrio from US market after study
Time:2024-05-21 08:16:10 Source:businessViews(143)
WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition.
Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.
The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS.
Previous:Elon Musk gets approval from FDA to implant his Neuralink brain chip into a second patient
Next:Amir Khan's £11.5m luxury wedding venue finally hosts its first marriage: Bride arrives on horse
You may also like
- Ship that caused Baltimore bridge collapse has been refloated
- Two women embark on 500
- Jessica Biel goes braless beneath plunging pink feather
- Western Hemisphere nations pledge to continue coordinating response to historic regional migration
- Strictly star Giovanni Pernice's former partner Rose Ayling
- China celebrates 30 years of internet access, boasting over 1 billion users
- Moment mysterious loud boom shakes houses as a huge flash lights up the night sky over Vegas
- Dua Lipa puts on sultry show in silk and lace as she teams a plunging corset with low
- Red Lobster seeks bankruptcy protection after closing some restaurants